Why Exact Sciences (EXAS) is on investors’ radar

Exact Sciences (EXAS) has drawn attention after a period of strong 1 year total return of 108.16% and past 3 months return of 19.88%, prompting closer scrutiny of its current valuation.

At a share price of US$103.31, Exact Sciences has seen a strong 1 year total shareholder return of 108.16%, while its 90 day share price return of 19.88% suggests momentum has recently picked up after a more muted start to the year.

If this kind of move in a cancer diagnostics stock has you looking wider in healthcare, it could be a good moment to scan 25 healthcare AI stocks for more potential ideas.

With the share price near US$103 and an intrinsic value estimate implying a 32% discount, plus a loss of US$207.9 million alongside growing revenue, you have to ask: is this a buying opportunity, or is the market already pricing in future growth?

Most Popular Narrative: 2% Undervalued

The most followed narrative pegs Exact Sciences' fair value at about US$105.81, just above the last close at US$103.31. This keeps the focus firmly on what is driving that small gap.

The ongoing demographic shift toward an aging population, together with Exact Sciences' broader early detection portfolio (Cologuard Plus, blood-based screening via Freenome, and the upcoming MCED test CancerGuard), is set to expand the addressable market significantly and position the company to capture future volume-driven revenue growth as cancer incidence increases.

Curious what sits behind that valuation edge? The narrative leans on steady top line expansion, margin uplift and a rich future earnings multiple that is not typical for this sector. The exact mix of growth forecasts, profitability targets and discount rate assumptions might surprise you.

Result: Fair Value of $105.81 (UNDERVALUED)

However, there are also clear watchpoints, including heavy reliance on Cologuard and uncertainty around future returns from costly blood based screening and MCED investments.

Next Steps

If this mix of optimism and caution has you thinking harder about Exact Sciences, it is worth checking the numbers yourself and forming a clear view quickly, starting with 4 key rewards.

Looking for more investment ideas?

If Exact Sciences has sharpened your interest, do not stop here. Use the Simply Wall Street Screener to line up your next round of stock ideas.

• Spot potential value opportunities early by checking companies our tools flag as 56 high quality undervalued stocks before they draw wider attention.
• Strengthen the quality of your watchlist by finding businesses from our solid balance sheet and fundamentals stocks screener (43 results) that pair financial resilience with room for future potential.
• Get ahead of the crowd by reviewing our screener containing 24 high quality undiscovered gems, where smaller names with strong fundamentals may not yet be widely followed.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.